However, in HER2+ breast cancer cells that have become resistant to lapatinib, HER3 phosphorylation can be regulated by EGFR-HER3 dimers, which were not responsive to inhibition by lapatinib or other EGFR TKIs. This evidence concerns the gene EGFR and breast cancer.